Analysts Expect VB Will Reach $224 Wednesday, May 24, 6:44 AM ET, by Market News Video Staff Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...
Surprising Analyst 12-Month Target For VB Wednesday, July 5, 6:19 AM ET, by Market News Video Staff Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...
Noteworthy Tuesday Option Activity: OMF, HOOD, IBRX Tuesday, October 24, 3:24 PM ET, by Market News Video Staff Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume ...
Commit To Purchase ImmunityBio At $2.50, Earn 26.7% Annualized Using Options
By Market News Video Staff, Friday, March 22, 11:49 AM ET
Investors considering a purchase of ImmunityBio Inc (NASDAQ:IBRX) shares, but cautious about paying the going market price of $6.14/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2025 put at the $2.50 strike, which has a bid at the time of this writing of 55 cents. Collecting that bid as the premium represents a 22% return against the $2.50 commitment, or a 26.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to IBRX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $2.50 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless ImmunityBio Inc sees its shares decline 59.7% and the contract is exercised (resulting in a cost basis of $1.95 per share before broker commissions, subtracting the 55 cents from $2.50), the only upside to the put seller is from collecting that premium for the 26.7% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for ImmunityBio Inc, and highlighting in green where the $2.50 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2025 put at the $2.50 strike for the 26.7% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for ImmunityBio Inc (considering the last 251 trading day closing values as well as today's price of $6.14) to be 153%. For other put options contract ideas at the various different available expirations, visit the IBRX Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Friday, the put volume among S&P 500 components was 957,516 contracts, with call volume at 1.18M, for a put:call ratio of 0.81 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers.
Find out which 15 call and put options traders are talking about today.
This Article's Word Cloud:IBRXImmunityBioJanuaryOptionsStockYieldBoostaboutamongannualizedbenefitbuyerscallcentschartcomparedconsideringcontractexercisedfillColorfromgoinghistorymarketmonthonlyoptionsotherowningpremiumpricerateratiorepresentsreturnsellersellingsharesharesstrikethanthattherethistodaytradingtrailingtwelveupsidewhichwould
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?
⤹
Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.
You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.